Tyra Biosciences Inc. (TYRA)
8.68
-0.04 (-0.46%)
At close: Apr 02, 2025, 3:59 PM
8.80
1.39%
After-hours: Apr 02, 2025, 07:56 PM EDT
Company Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.
Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.
In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots.
Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Tyra Biosciences Inc.
| Country | United States |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Dr. Todd Harris Ph.D. |
Contact Details
Address: 2656 State Street Carlsbad, California United States | |
| Website | https://www.tyra.bio |
Stock Details
| Ticker Symbol | TYRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001863127 |
| CUSIP Number | 90240B106 |
| ISIN Number | US90240B1061 |
| Employer ID | 83-1476348 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, President, Chief Executive Officer, Secretary, Treasurer & Director |
| Daniel Bensen | Co-Founder & Chief Operating Officer |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer |
| Ali D. Fawaz J.D. | General Counsel |
| Dr. Douglas Warner M.D. | Chief Medical Officer |
| Dr. Piyush R. Patel Ph.D. | Chief Development Officer |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer |
| Erik Goluboff | Senior Vice President of Clinical Development |
| Liz Pagano | Senior Vice President of Human Resources |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 4 | Filing |
| Mar 18, 2025 | 4 | Filing |
| Mar 06, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 07, 2025 | 4 | Filing |
| Jan 31, 2025 | 4 | Filing |
| Jan 31, 2025 | 3 | Filing |